Onco Actu du 31 mai 2016

	2.6 Etiologie - Environnement
EU to propose shorter glyphosate license renewal: sources [Reuters] The EU executive will put a new proposal for a license renewal of between one and two years to experts from the EU's 28 nations on June 6, according to EU sources.
	4. Dépistage, diagnostic et pronostic
European Molecular Diagnostics in Cancer Testing Industry 2016 Market Research Report [ReportsnReports] The report focuses on European major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information.
	5.2.2 Pharma - Fusions & Acquisitions
Jazz Pharmaceuticals Nears Deal to Buy Celator for About $1.5 Billion [Wall Street Journal] Less than three months ago, Celator announced positive results for a clinical trial of a leukemia drug. The therapy, Vyxeos, aims to treat a blood cancer known as acute myeloid leukemia with two available drugs in a new formulation.
	5.2.3 Pharma - économie
Roche and Novartis face off in biosimilar drug battle [Reuters] With a copycat of Roche's blood cancer drug Rituxan pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7 billion Swiss francs ($7.1 billion). But Roche is fighting back with a new medicine, Gazyva, which it contends is better than Rituxan.
	5.3.4 Traitements - AMM (FDA, EMA)
Six medicines win backing for EU approval [PharmaTimes] Three new generic medicines also won CHMP backing: Bortezomib Hospira (bortezomib) and Bortezomib Sun (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma; and Pemetrexed Fresenius Kabi (pemetrexed) for the treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer.
Roche’s subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia [Roche] Following the approval of MabThera SC (1400 mg) for common forms of non-Hodgkin lymphoma in March 2014, this is the second European approval for the formulation.
Roche's MabTherea shot gets EU OK for chronic lymphocytic leukemia [Reuters] The European Commission approved the injection for people with previously untreated and relapsed/refractory forms of the disease.
	6.10 Politiques
Our cancer care is not giving us value for money [The Telegraph] British spending on cancer drugs, at $32,600 per case, was significantly outspent only by Italy ($44,000 per case) and the US ($74,000). The picture of the UK as the poor man of Europe in cancer spending does not hold water.
	6.6 Publications
Why aren’t there more women in science? The industry structure is sexist [The Guardian] Why are so few women publishing scientific papers? It is a question that has been posed by New Scientist magazine, as it reports that in medicine, female authorship of scientific papers has started to go backwards. Since 2009, the proportion of women as lead authors has gone down.
	6.9 Controverses
Cancer moonshot and slow-learners [The Mermaid's Tale] In this sense all the marketing rhetoric about 'precision' genomic medicine is playing a game with the public, and the game is for money--research money among other things. There's no cure for mortality or the reality of aging.